Cory Fowler
Payments from drug & device makers
Across 138 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biohaven Pharmaceuticals, Inc.$861
- Nestle Healthcare Nutrition Inc.$172
- Biohaven Pharmaceutical Holding Company Ltd.$107
- Almatica Pharma LLC$74
- Lilly USA, LLC$67
- plus $320 from 12 others
What the payments were for
- Consulting fees$80024%
- Food & beverage$2,47276%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 95 | $1,671 |
| Biohaven Pharmaceuticals, Inc. | 4 | $861 |
| Nestle Healthcare Nutrition Inc. | 8 | $172 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $107 |
| Almatica Pharma LLC | 4 | $74 |
| Lilly USA, LLC | 4 | $67 |
| Pfizer | 4 | $66 |
| Virtus Pharmaceuticals LLC | 3 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Amgen | 1 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| QOL Medical, LLC | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Exact Sciences | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
How this compares
$3,272 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Np ThyroidThyroid,pork | 27 | $1,868 |
| ProgesteroneProgesterone, Micronized | 57 | $1,676 |
| Liothyronine Sodium | 51 | $1,173 |
| Testosterone Cypionate | 11 | $622 |
| Levothyroxine Sodium | 40 | $270 |
| Zolpidem Tartrate | 22 | $175 |
| Omeprazole | 13 | $123 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $118 |
| Finasteride | 13 | $113 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 13 | $48 |
| Allopurinol | 17 | $42 |
| Clonazepam | 14 | $39 |
| Losartan Potassium | 17 | $37 |
| Lorazepam | 13 | $31 |
| Metformin Hcl ErMetformin Hcl | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acella Pharmaceuticals, LLCNp Thyroid | $14 | $1,86827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.
Other family in Provo
- Kindra HuntProvo$118K
- Judd HunterProvo$32K
- Katelyn SianoProvo$29K
- Michael RobinsonProvo$16K
- Darin UsherProvo$15K
- Ashley RadmallProvo$8K
- Kylee MaliwaukiProvo$8K
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.